Scientists Say This Simple Supplement May Actually Reverse Heart Disease

Key Takeaways

• Tricaprin reduced arterial triglyceride deposits in two TGCV patients
• Improvement occurred without changes in standard blood‑lipid levels
• TGCV often co‑exists with diabetes and dialysis patients
• Phase IIa trial testing CNT‑01 (tricaprin) underway in Japan
• If validated, intracellular lipolysis could complement statin therapy

Pulse Analysis

The discovery of triglyceride deposit cardiomyovasculopathy (TGCV) has reshaped cardiology’s view of plaque formation. Unlike classic atherosclerosis driven by cholesterol, TGCV stems from defective intracellular breakdown of triglycerides, leading to fatty deposits within vascular smooth‑muscle cells. This condition disproportionately affects diabetics and patients on hemodialysis, often masquerading as typical coronary artery disease and slipping past standard diagnostics. By targeting the metabolic fault at the cellular level, researchers hope to address a hidden driver of heart‑attack risk that current therapies overlook.

Tricaprin, a medium‑chain triglyceride supplement, emerged as a candidate because it can stimulate intracellular fat oxidation. In the Osaka University case series, two patients in their 60s with refractory angina and confirmed TGCV experienced symptom relief and measurable regression of arterial lesions after several months of daily tricaprin intake. Notably, conventional lipid panels—LDL, HDL, and total cholesterol—showed little change, underscoring a mechanism distinct from statin‑mediated cholesterol reduction. Imaging modalities such as coronary CT angiography and iodine‑123‑β‑methyl‑p‑iodophenylpentadecanoic acid scintigraphy confirmed reduced triglyceride volume and enhanced myocardial lipolysis.

The broader implications hinge on scaling these early results. A Phase IIa trial (CNT‑01) is now testing a refined tricaprin formulation in a larger TGCV cohort, aiming to validate safety, optimal dosing, and reproducibility of arterial remodeling. If successful, tricaprin could become an adjunct to existing lipid‑lowering drugs, offering a dual‑pathway strategy: extracellular cholesterol management plus intracellular triglyceride clearance. Such an approach could transform care for patients who remain symptomatic despite aggressive statin therapy, stenting, or bypass surgery, and may inspire further research into metabolic modulation of cardiovascular disease.